Need a specific person's email?
Browse Incendia Therapeutics's employee directory (about 23 employees) and reveal verified emails free.
Incendia Therapeutics's most common email format is First.Last@parthenontx.com (ex. John.Doe@parthenontx.com), used for 95% of parthenontx.com addresses. Incendia Therapeutics uses 3 email patterns.
| Format | Example | Share of parthenontx.com |
|---|---|---|
| First.Last@parthenontx.comMost common | John.Doe@parthenontx.com | |
| Middle@parthenontx.com | Michael@parthenontx.com | |
| First@parthenontx.com | John@parthenontx.com |
Browse Incendia Therapeutics's employee directory (about 23 employees) and reveal verified emails free.
Biotechnology ResearchMassachusetts, United States11-50 Employees
Incendia Therapeutics is a small- to mid-sized, clinical-stage biotechnology company based in Cambridge, Massachusetts. It focuses on discovering and developing monoclonal antibody therapies that disrupt the tumor microenvironment to improve cancer outcomes, with an emphasis on immune-excluded solid tumors where barriers limit immune cell infiltration and therapeutic reach. The company's lead program, PRTH-101, is a novel antibody that binds to and inhibits DDR1, an element of the tumor microenvironment expressed by cancer cells across multiple solid tumor types, and the firm is enrolling patients in a Phase 1c trial for advanced solid tumors including thymic carcinoma. In October 2024, Delfi Diagnostics announced a partnership with Incendia to apply an advanced treatment-monitoring test within the ongoing Phase 1 trial.
Most common format
First.Last@parthenontx.com
Example: John.Doe@parthenontx.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.